Hepatitis E virus (HEV), the main etiologic agent of enterically transmitted acute hepatitis in developing countries, is now recognized as an emerging agent of autochthonous disease and chronic hepatitis E in immunocompromised patients in Europe where HEV infection is probably zoonotically acquired. We describe the first human case of acute HEV infection with two genotype 3 viruses in a French kidney transplant recipient, probably acquired through consumption of uncooked pig liver sausage (figatellu). The patient presented two viral sequences nearly identical to sequences recovered from figatelli. Autochthonous co-infections with different genotype 3 HEV strains can occur in our geographical area.

1.
Purcell RH, Emerson SU: Hepatitis E: an emerging awareness of an old disease. J Hepatol 2008;48:494–503.
2.
Lu L, Li C, Hagedorn CH: Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 2006;16:5–36.
3.
Legrand-Abravanel F, Mansuy JM, Dubois M, et al: Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis 2009;15:110–114.
4.
Kamar N, Selves J, Mansuy JM, et al: Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811–817.
5.
Gérolami R, Moal V, Colson P: Chronic hepatitis E with cirrhosis in a kidney-transplant recipient. N Engl J Med 2008;358:859–860.
6.
Pischke S, Suneetha PV, Baechlein C, et al: Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010;16:74–82.
7.
Haagsma EB, Niesters HGM, van den Berg AP, et al: Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009;15:1225–1228.
8.
Mansuy JM, Bendall R, Legrand-Abravanel F, et al: Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 2011;17: 2309–2312.
9.
Kaba M, Davoust B, Marié JL, et al: Detection of hepatitis E virus in wild boar (Sus scrofa) livers. Vet J 2010;186:259–261.
10.
Colson P, Borentain P, Queyriaux B, et al: Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis 2010;202:825–834.
11.
Takahashi M, Nishizawa T, Yoshikawa A, et al: Identification of two distinct genotypes of hepatitis E virus in a Japanese patient with acute hepatitis who had not travelled abroad. J Gen Virol 2002;83:1931–1940.
12.
Colson P, Moal V, Borentain P, et al: Seroprevalence and outcome of hepatitis E infection in organ transplanted patients (abstract). Hepatology 2008;50:s732A.
13.
Li Z, Yu S, Dong S, et al: Reduced prevalence of genotype 3 HEV in Shanghai pig farms and hypothetical homeostasis of porcine HEV reservoir. Vet Microbiol 2009;137:184–189.
14.
Purdy MA, Khudyakov YE: Evolutionary history and population dynamics of hepatitis E virus. PLoS One 2010;5:e14376.
15.
Grandadam M, Tebbal S, Caron M, et al: Evidence for hepatitis E virus quasispecies. J Gen Virol 2004;85:3189–3194.
16.
Kamar N, Abravanel F, Selves J, et al: Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 2010;89:353–360.
17.
Colson P, Dhiver C, Poizot-Martin I, et al: Acute and chronic hepatitis E in patients infected with human immunodeficiency virus. J Viral Hepat 2011;18:227–228.
18.
Alric L, Bonnet D, Laurent G, et al: Chronic hepatitis E virus infection: successful virologic response to pegylated interferon-α therapy. Ann Intern Med 2010;153:135–136.
19.
Covic A, Abramowicz D, Bruchfeld A, et al: Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 2009;24:719–727.
20.
Kamar N, Rostaing L, Abravanel F, et al: Ribavirin therapy inhibits viral replication in patients with chronic hepatitis E virus infection. Gastroenterology 2010;139:1612–1618.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.